 NEW HAVEN, Conn., Feb. 04, 2021 GLOBE NEWSWIRE -- BioXcel Therapeutics, Inc. BioXcel or the Company Nasdaq: BTAI, a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that an update from its ongoing Phase 1b2 trial of BXCL701, the Companys investigational, oral innate immunity activator, in aggressive forms of prostate cancer will be presented in a poster session at the virtual 2021 ASCO Genitourinary ASCO GU Cancers Symposium. ASCO GU is being held from Thursday, February 11, 2021 to Saturday, February 13, 2021. 